Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09VBE
|
|||
| Former ID |
DNCL001873
|
|||
| Drug Name |
Elinogrel
|
|||
| Synonyms |
Elinogrel; 936500-94-6; UNII-915Y8E749J; 915Y8E749J; 5-CHLORO-N-[[[4-[6-FLUORO-1,4-DIHYDRO-7-(METHYLAMINO)-2,4-DIOXO-3(2H)-QUINAZOLINYL]PHENYL]AMINO]CARBONYL]-2-THIOPHENESULFONAMIDE; PRT-060128; Elinogrel [USAN:INN]; PRT 060128; Elinogrel (USAN/INN); SCHEMBL160663; CHEMBL2103828; MolPort-035-941-202; ZINC43153259; BDBM50397204; AKOS025142086; NCGC00387478-01; AN-26210; FT-0724857; D09607; 500C946; 1-(5-chlorothiophen-2-yl)sulfonyl-3-[4-[6-fluoro-7-(methylamino)-2,4-dioxo-1H-quinazolin-3-yl]phenyl]urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Myocardial infarction [ICD-11: BA41-BA43; ICD-9: 410] | Phase 1 | [1] | |
| Company |
Novartis Pharmaceuticals; Portola Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H15ClFN5O5S2
|
|||
| Canonical SMILES |
CNC1=C(C=C2C(=C1)NC(=O)N(C2=O)C3=CC=C(C=C3)NC(=O)NS(=O)(=O)C4=CC=C(S4)Cl)F
|
|||
| InChI |
1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)
|
|||
| InChIKey |
LGSDFTPAICUONK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 936500-94-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | P2Y purinoceptor 12 (P2RY12) | Target Info | Antagonist | [2] |
| KEGG Pathway | Platelet activation | |||
| Reactome | P2Y receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00984113) Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment. U.S. National Institutes of Health. | |||
| REF 2 | Elinogrel, a reversible P2Y12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events. Curr Opin Investig Drugs. 2010 Mar;11(3):340-8. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.